Main clinical characteristics and functional PET parameters at presentation in the studied cohort (n = 103)
| Characteristics . | No. of patients (%) . | Median (IQR) . |
|---|---|---|
| Age, years | ||
| ≤60 y | 97 (94) | |
| ≤40 y | 75 (73) | |
| Female sex | 63 (61) | |
| ECOG Performance Status >1 | 15 (15) | |
| Mediastinal bulky disease >10 cm | 54 (52) | |
| Ann Arbor stage I-II | 97 (94) | |
| LDH > normal upper value | 77 (75) | |
| Low and low-intermediate IPI risk | 99 (96) | |
| Low and low-intermediate aaIPI risk | 82 (85) | |
| Front-line treatment | ||
| R-CHOP or R-CHOP like regimen* | 16 (16) | |
| R-VACOP-B or R-MACOP-B regimen* | 87 (84) | |
| With RT | 93 (90) | |
| SUVmax | 18.8 (15.5-23) | |
| Elevated (>22.2)† | 30 (29) | |
| MTV | 406 (267-641) | |
| Elevated (>703, PFS cut-point)† | 20 (19) | |
| TLG | 4261 (2363-6398) | |
| Elevated (>5814, PFS cut-point)† | 33 (32) |
| Characteristics . | No. of patients (%) . | Median (IQR) . |
|---|---|---|
| Age, years | ||
| ≤60 y | 97 (94) | |
| ≤40 y | 75 (73) | |
| Female sex | 63 (61) | |
| ECOG Performance Status >1 | 15 (15) | |
| Mediastinal bulky disease >10 cm | 54 (52) | |
| Ann Arbor stage I-II | 97 (94) | |
| LDH > normal upper value | 77 (75) | |
| Low and low-intermediate IPI risk | 99 (96) | |
| Low and low-intermediate aaIPI risk | 82 (85) | |
| Front-line treatment | ||
| R-CHOP or R-CHOP like regimen* | 16 (16) | |
| R-VACOP-B or R-MACOP-B regimen* | 87 (84) | |
| With RT | 93 (90) | |
| SUVmax | 18.8 (15.5-23) | |
| Elevated (>22.2)† | 30 (29) | |
| MTV | 406 (267-641) | |
| Elevated (>703, PFS cut-point)† | 20 (19) | |
| TLG | 4261 (2363-6398) | |
| Elevated (>5814, PFS cut-point)† | 33 (32) |
aaIPI, age-adjusted IPI; LDH, serum lactate dehydrogenase; RT, consolidation mediastinal radiotherapy.
Details on the immunochemotherapy regimens and radiotherapy plans have been previously reported.19
Dichotomized using receiver operating characteristics analysis to identify the optimal cut point, as previously reported.24